Sign up to save your data!
Some tips to help get started:
Processing...
There are 746 active trials for advanced/metastatic other solid tumor. Click on a trial to see more information. Note that this list also includes some trials that are only for specific cancer types like lung cancer. To see trials customized to a patient, please select a patient above.
746 trials meet filter criteria.
Sort by:
HealthScout AI summary: Adults with metastatic solid tumors (mainly gastric, non-small cell lung, triple-negative breast, and cervical cancers) expressing KK-LC-1 and positive for HLA-A*01:01, who have exhausted standard therapies, receive lymphodepleting chemotherapy followed by a single infusion of autologous T cells engineered to express a T cell receptor targeting the KK-LC-1 antigen, plus aldesleukin. This trial investigates the safety and dosing of this KK-LC-1-specific TCR-T cell therapy.
ClinicalTrials.gov ID: NCT05483491
HealthScout AI summary: This trial enrolls adults with advanced solid tumors harboring activating PIK3CA mutations who have progressed after standard therapy, including a cohort specifically for HR+/HER2- advanced breast cancer with prior CDK4/6 inhibitor and anti-estrogen exposure. Patients receive ETX-636, an oral, mutant-selective PI3Kα inhibitor and degrader, either as monotherapy or combined with fulvestrant.
ClinicalTrials.gov ID: NCT06993844
HealthScout AI summary: This trial enrolls adults with metastatic or locally advanced, unresectable HER2-negative breast cancer (either hormone receptor-positive or triple negative) who have received prior chemotherapy and hormonal therapy, and tests the combination of alpelisib (a PI3K-alpha inhibitor) and sacituzumab govitecan (a Trop-2-directed antibody-drug conjugate) to determine safety and dose for future studies. Patients with stable brain metastases are eligible.
ClinicalTrials.gov ID: NCT05143229
HealthScout AI summary: Eligible patients are adults with advanced, unresectable, or recurrent solid tumors or lymphomas that have progressed on standard therapy and have at least one injectable, measurable lesion; they will receive intratumoral ONM-501, a dual-activating STING agonist, either alone or in combination with intravenous cemiplimab, a PD-1 inhibitor. Key exclusions include active or untreated brain metastases, recent major surgery, and active autoimmune disease (for combination cohorts).
ClinicalTrials.gov ID: NCT06022029
HealthScout AI summary: This trial enrolls adults with newly diagnosed, untreated metastatic triple negative breast cancer that is negative for PD-L1, evaluating nab-paclitaxel plus durvalumab (PD-L1 inhibitor) and tremelimumab (CTLA-4 inhibitor), with or without the addition of a personalized neoantigen peptide vaccine plus poly-ICLC as an immunologic adjuvant. Patients must have accessible tumor tissue, good performance status, and meet organ function requirements.
ClinicalTrials.gov ID: NCT03606967
HealthScout AI summary: This trial enrolls adults with advanced solid tumors, particularly breast cancer (including HR+/HER2-, HER2+, and HER2-low subtypes), or select non-breast cancers, all of which harbor a PI3KαH1047R mutation; participants receive OKI-219, a highly selective PI3KαH1047R inhibitor, as monotherapy or in combination with fulvestrant or trastuzumab. Eligible patients must have measurable disease, ECOG 0-1, and adequate organ function.
ClinicalTrials.gov ID: NCT06239467
HealthScout AI summary: This trial enrolls adults with advanced solid tumors harboring deleterious or suspected deleterious BRCA1/2 or other homologous recombination repair mutations—such as HER2-negative BRCA-mutant breast cancer, high-grade serous ovarian or fallopian tube cancer, metastatic castration-resistant prostate cancer, and pancreatic cancer—who have progressed on, are intolerant to, or are ineligible for standard therapies (including PARP inhibitors). Patients receive the investigational oral USP1 inhibitor XL309, which disrupts DNA repair, as monotherapy or in combination with olaparib.
ClinicalTrials.gov ID: NCT05932862
HealthScout AI summary: This trial enrolls adults with advanced or metastatic hepatocellular, renal cell, breast, ovarian/fallopian, or endometrial/primary peritoneal cancers involving the abdomen or thorax who have progressed on or are intolerant to standard therapies, and evaluates safety of Tumor Treating Fields (TTF) in combination with either cabozantinib (a multi-kinase inhibitor targeting MET, VEGFR, and AXL) or nab-paclitaxel plus atezolizumab (a PD-L1 inhibitor).
ClinicalTrials.gov ID: NCT05092373
HealthScout AI summary: This trial enrolls adults with metastatic, ER+/HER2-, GRPR-positive breast cancer who have progressed on prior endocrine therapy plus a CDK4/6 inhibitor, and evaluates the combination of capecitabine with [177Lu]Lu-NeoB, a novel radioligand that selectively targets GRPR-positive tumor cells with localized radiation. Prior capecitabine or radiopharmaceutical therapy is not permitted, and GRPR-positivity is confirmed by [68Ga]Ga-NeoB PET imaging.
ClinicalTrials.gov ID: NCT06247995
HealthScout AI summary: Adult patients with advanced solid tumors that are HLA-A*02:01 positive and harbor the p53 R175H mutation (confirmed by testing) receive CLSP-1025, a bispecific T-cell engager targeting the p53 R175H mutant peptide on tumor cells, as monotherapy. Prior p53 R175H-directed therapy, germline p53 mutations, and several comorbidities are exclusion criteria.
ClinicalTrials.gov ID: NCT06778863
